Proactive Investors - Run By Investors For Investors

Genedrive receives grant award for NHS point-of-care test

The AIM-listed firm said the award is for the development and implementation of a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children
medical laboratory
Genedrive said the project is expected to commence immediately

Genedrive PLC (LON:GDR) sad it has received a multi-partner grant award from the UK National Institute for Health Research’s Invention for Innovation programme for NHS point-of-care test.

The AIM-listed firm said the award is for the development and implementation of a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children.

READ: Genedrive to sell contract research and pharmacogenomics divisions for up to £1.9mln

The company said certain individuals develop irreversible hearing loss when exposed to antibiotic gentamicin. A Genedrive test is targeted to allow genetic results to be available within an hour, allowing alternative antibiotics to be used instead.

Genedrive said the project is expected to commence immediately, with an expected development phase of one year followed by a trial implementation phase in selected NHS hospitals in year two.

The company will then target the release of a Genedrive test within the NHS and more broadly. 

Genedrive said it expects to account for its £550,000 share of the project funding as income which will be matched to costs incurred over the two-year project. 

David Budd, chief executive officer of Genedrive PLC, said: "The application of Genedrive in an urgent healthcare setting is an excellent example of how a rapid, affordable, point-of-care test could impact patients' treatment and quality of life.”

“The NHS is a huge market place and, if adopted, this would be the first placement of Genedrive in a developed world healthcare setting. The project is an exciting opportunity to expand the markets in which Genedrive is used."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use